Eri Takeshita

Eri Takeshita

Auto-generated profile, based on publicly available information

Eri Takeshita

Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Internal Medicine
Verified
Journal Article
Open access
PDF file
NONorihiro Okamoto
Norihiro Okamoto
NTNaoyuki Tominaga
Naoyuki Tominaga
YSYASUHISA SAKATA
YASUHISA SAKATA
MHMegumi Hara
Megumi Hara
TYTakahiro Yukimoto
Takahiro Yukimoto
KFKazuma Fujimoto
Kazuma Fujimoto
Objective This historical control study was performed to evaluate i) the rebleeding rate of bleeding colon diverticula treated with endoscopic band ligation (EBL) versus endoscopic clipping (EC) and ii) risk factors for rebleeding of diverticula initially treated by endoscopic hemostasis. Methods From January 2010 to December 2012, 68 patients were treated with EC, and from January 2013 to August 2016, 67 patients were treated with EBL. All patients in each group were followed up for one year to check for rebleeding. Results The rebleeding rate was lower in the EBL group (7 of 67, 10%) than in the EC group (21 of 68, 31%; p<0.01). This difference was mainly due to the lower rebleeding rate from the same hemorrhagic diverticulum initially treated by hemostasis (EBL: 4 of 67, 6%; EC: 15 of 68, 22%; p<0.01). The time span until rebleeding in the EBL group was ≤1 week. A multivariate analysis indicated that bleeding from the diverticula on the right side of the colon was a high-risk factor for rebleeding from the diverticula (odds ratio, 4.48; 95% confidence interval, 1.22-16.46; p=0.02). Conclusion The low rebleeding rate in the EBL group was attributed to the low degree of rebleeding from the same diverticulum, indicating that EBL was superior to EC in preventing rebleeding of an initially treated diverticulum.

1 November 2018 in Brain and Development
Verified
Journal Article
Closed access
ETEri Takeshita
Eri Takeshita
HKHirofumi Komaki
Hirofumi Komaki
HTHisateru Tachimori
Hisateru Tachimori
KMKazuhisa Miyoshi
Kazuhisa Miyoshi
IYIkuo Yamamiya
Ikuo Yamamiya
MSMasayuki Sasaki
Masayuki Sasaki

1 September 2018 in Brain and Development
Verified
Journal Article
Closed access
RTRyo Takeguchi
Ryo Takeguchi
KHKazuhiro Haginoya
Kazuhiro Haginoya
YUYuri Uchiyama
Yuri Uchiyama
AFAtsushi Fujita
Atsushi Fujita
MNMichiaki Nagura
Michiaki Nagura
MSMasayuki Sasaki
Masayuki Sasaki

1 June 2017 in Neuromuscular Disorders
Verified
Journal Article
Closed access
ETEri Takeshita
Eri Takeshita
NMNarihiro Minami
Narihiro Minami
KMKumiko Minami
Kumiko Minami
MSMikiya Suzuki
Mikiya Suzuki
TATakeya Awashima
Takeya Awashima
MSMasayuki Sasaki
Masayuki Sasaki

21 January 2023 in Brain and Development
Verified
Journal Article
Closed access
SWShiena Watanabe
Shiena Watanabe
MLMing Lei
Ming Lei
ENEiji Nakagawa
Eiji Nakagawa
ETEri Takeshita
Eri Takeshita
KIKei-ichiro Inamori
Kei-ichiro Inamori
JIJin-Ichi Inokuchi
Jin-Ichi Inokuchi

1 February 2025 in Neurology Genetics
Verified
Journal Article
Open access
Akinori NakamuraAkinori Nakamura
Akinori Nakamura
TMTsuyoshi Matsumura
Tsuyoshi Matsumura
KOKatsuhisa Ogata
Katsuhisa Ogata
MMMadoka Mori-Yoshimura
Madoka Mori-Yoshimura
ETEri Takeshita
Eri Takeshita
HKHirofumi Komaki
Hirofumi Komaki
Becker muscular dystrophy (BMD) is an allelic disorder of Duchenne muscular dystrophy (DMD) in which pathogenic variants in DMD cause progressive worsening of motor dysfunction, muscle weakness and atrophy, and death due to respiratory and cardiac failure. BMD often has in-frame deletions that preserve the amino acid reading frame, but there are some cases with microvariants or duplications. In recent years, the importance of therapeutic development and care for BMD has been emphasized. Therefore, the purpose of this study was to understand the clinical characteristics of BMD patients with microvariants or duplications and to determine the genotype-phenotype relationship. The study focused on patients with pathogenic microvariants or duplications in DMD who were ambulatory after 16 years of age or had specific muscle biopsy results between June 13, 2017, and March 31, 2023. Informed consent was obtained from the patients or their surrogates. Data concerning DMD variants, muscle biopsy findings, skeletal muscle, respiratory and cardiac function, and CNS involvement were collected and analyzed statistically. Thirty-three patients with BMD had pathogenic microvariants (missense variants, nonsense variants, splice site variants, and other microvariants), and 16 patients had in-frame duplications in DMD. Many patients with microvariants had abnormal ECG findings. The effect of variant type on patient outcomes varied. Regardless of the type of microvariant, skeletal muscle and respiratory dysfunction was more severe in mutants of the cysteine-rich/C-terminal domain than in rod domain mutants. On the other hand, there was no significant difference in the complication rate of CNS disorders among the 3 domains of dystrophin. Microvariant forms, in particular, tend to vary in clinical severity according to the site of the dystrophin protein mutation rather than the type of pathogenic variant. The results of this study may be useful for genetic counseling, care, and treatment of patients with BMD.